The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Researchers are examining why insurance plans frequently restrict access to GLP-1 medications like Ozempic and Wegovy despite their proven health benefits. The study highlights that while these drugs are cost-effective, their high price and the massive number of eligible patients create a significant budget impact for insurers.
GLP-1 medications have been shown to improve health and offer strong value for their price, yet many insurance plans continue to restrict access. Researchers at the University of Mississippi are investigating the financial and practical reasons behind those limits, along with the consequences for patients.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in